治疗前增强MRI对乳腺癌患者新辅助化疗后病理完全缓解的预测性:文献结果的验证
回顾性纳入203例乳腺浸润性导管癌(非特殊型)患者,治疗前MRI、新辅助化疗及手术后评估病理完全缓解(pCR),从文献筛选43个基于MRI的影像组学特征进行验证;仅1个特征在全数据集与化疗反应相关,11个特征在至少一种分子亚型中相关,但均未通过多重比较校正,约四分之三既往报道的特征未获验证。
要点
- 既往报道的43个MRI影像组学特征中,仅1个在全数据集与pCR相关,11个在至少一种亚型中相关。
- 所有关联均未通过多重比较校正。
- 约四分之三既往报道可预测pCR的影像组学特征在本数据集中未获验证。
核心结论
- 约四分之三既往报道可预测pCR的影像组学特征在本数据集中未获验证(即使未进行多重比较校正),对既往发表结果的有效性提出担忧;需要大型多中心研究评估影像组学特征预测pCR的真实潜力。
研究设计与样本
- 回顾性研究,纳入在Champalimaud Foundation接受治疗前MRI、新辅助化疗和手术的非特殊型乳腺癌女性,数据集包括203个肿瘤;经机构伦理委员会批准;通过PubMed数据库检索近5年发表的英文论文,仅选取注射钆后1分钟T1加权图像上符合影像生物标志物标准化倡议(IBSI)且报道可预测pCR的MRI特征进行测试。
诊断标准与关键数值
- 从文献中筛选43个基于MRI的特征进行测试;pCR在86个肿瘤中观察到(管腔B样亚型43/130、三阴性亚型30/57、HER2富集替代分子亚型13/16);仅1个MRI特征在全数据集与NAC反应显著相关,11个特征在至少一种肿瘤亚型中与NAC反应相关;这些关联均未通过多重比较校正。
局限性
- 既往报道的影像组学特征结果不一致。
- 约四分之三既往报道可预测pCR的影像组学特征在本数据集中未获验证(即使未进行多重比较校正)。
- 需要大型多中心研究评估影像组学特征预测pCR的真实潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Pretreatment MRI-based features predictive of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients have been reported, with inconsistent results. We aimed to evaluate which of these features could predict pCR in our dataset.
MATERIALS AND METHODS: Retrospective study including women with BC of no special type submitted to pretreatment MRI, NAC, and surgery at Champalimaud Foundation, and approved by the institutional Ethics Committee. A literature review was performed on the PubMed database, including only English-written papers published in the last 5 years. Only MRI-based features from the one-minute postgadolinium injection on T1-weighted images compliant with the Image Biomarker Standardisation Initiative (IBSI) and reported to be predictive of pCR were selected to be tested. The selected features were extracted from the pretreatment MRI of each primary BC and statistically compared between responders (pCR) and non-responders (non-pCR).
RESULTS: Our dataset included 203 tumors. pCR was observed in 86 tumors (43/130 luminal B-like, 30/57 triple-negative and 13/16 HER2-enriched surrogate molecular subtypes). After the literature review, 43 MRI-based features were selected to be tested. Only one MRI-based feature was significantly associated with NAC response in the entire dataset and 11 features were associated with NAC response in at least one tumor subtype. However, none of these associations survived correction for multiple comparisons.
CONCLUSIONS: Approximately ¾ of the radiomic features previously reported as predictive of pCR were not confirmed in our dataset (even without correction for multiple comparisons). This raises concerns about the validity of previously published findings. Large multicentre studies are needed to evaluate the real potential of radiomic features on pCR prediction.
引用
- Oliveira C, Oliveira F, Constantino C, et al. Predictability of pretreatment contrast-enhanced MRI for pathological complete response after neoadjuvant chemotherapy in breast cancer patients: validation of the literature results. Eur J Radiol. 2025. PMID: 41138318. doi:10.1016/j.ejrad.2025.112485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。